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ABSTRACT
Previous functional and deletion mapping studies on cervical cancer
(CC) have implicated one or more tumor suppressor genes (TSGs) on
chromosome 11 at q13 and q22–24 regions. Of these, the 11q22–24 region
exhibits frequent allelic deletions in a variety of solid tumor types, sug-
gesting the presence of critical genes for tumor suppression in this region.
However, the precise region of deletion on 11q is not clearly defined in CC.
In an attempt to accurately map the deleted region, we performed an
extensive loss of heterozygosity (LOH) mapping in 58 tumors using 25
polymorphic loci on both the short and long arms. The pattern of LOH
identified three sites of deletions, two on 11p (p15.11–p15.3 and p12–13),
and one on 11q (q23.1–q23.2). The 11q23.1–q23.2 exhibited highest fre-
quency (60.6%) of deletions, suggesting that this could be the site of a
candidate TSG in CC. The minimal deletion at 11q23.1–23.2 was re-
stricted to a 6-cM region between 123.5 and 129.5 cM genetic distance on
chromosome 11, identifying the site of a potential TSG important in the
pathogenesis of CC. At least five known genes and 28 UniGene clusters
were mapped to the present commonly deleted region. In addition, we
have excluded a previously known TSG PPP2R1B at 11q23 as a deletion
target in CC. The definition of the minimal deletion and the availability of
expressed sequence resources should facilitate the identification of the
candidate TSG.
INTRODUCTION
CC3 is a substantial public health issue among women worldwide,
causing high mortality, and the incidence is rising in certain countries
(1). Most invasive CCs are believed to be preceded by distinct
preinvasive changes called CINs (CINI–CINIII), which represents a
pathological continuum from mild to severe epithelial dysplasias.
Biological behavior of cervical precursor lesions vary in which only a
fraction of higher-grade dysplastic and preinvasive lesions progress to
invasive cancer (2–5). Most precancerous and preinvasive lesions are
readily curable, whereas the prognosis of invasive CCs are generally
poor. The genetic events that initiate the multistep pathway in cervical
tumorigenesis and cause invasion are of considerable importance in
understanding the molecular basis of CCs. A large body of evidence
has implicated infection of high-risk HPV types as the critical etio-
logical factor in CCs in which HPV E6 and HPV E7 proteins interact
with critical cell cycle check point genes p53 and pRB, respectively,
resulting in inactivation of these genes (6). However, epidemiological
data suggest that only a certain fraction of HPV-infected CIN lesions
progress to invasive CCs with variable latency periods (2–4). These
data, therefore, suggest that additional genetic alterations may be
necessary for the progression of CCs. Delineation of such genetic
changes may be of relevance in understanding cervical carcinogenesis
and will have implications in early detection and identification of
high-risk lesions.
Molecular genetic studies of CCs have identified frequent LOH
affecting multiple chromosomal regions such as 3p, 5p, 6p, and 11q
(7–10), suggesting the presence of TSGs in these regions. The func-
tional evidence for the presence of a TSG in CC was first identified on
chromosome 11 by somatic cell hybrid studies using HeLa cells (11)
and subsequent analysis in other CC cell lines (12–14). Pursuing these
studies, chromosome 11 has been shown consistently to exhibit LOH
at different regions, 11q13 and 11q22–23 (15–17). Although these
data provide strong evidence for the presence of a TSG on chromo-
some 11 relevant to CC, the critical region or the gene involved in the
development of this tumor is not yet identified. In the present study,
we defined a common minimal deletion at 11q23 that spans a 6-cM
genetic distance by LOH analysis and excluded the PPP2R1B gene at
11q23 as a target of deletion, which was shown earlier to be mutated
in other tumor types (18).
MATERIALS AND METHODS
Tumor and Normal Tissues. A total of 58 tumor biopsies derived from
previously untreated primary invasive CCs and the corresponding peripheral
blood samples comprised the material for the study. The tissues were ascer-
tained from patients treated at the Instituto Nacional de Cancerologia (Santa Fe
de Bogota, Colombia) after appropriate informed consent and the approval of
the protocol by the institutional review board. Clinically, the tumors were
classified by Fe´de´ration International des Gynaecologistes et Obstetristes class
1B (n 5 3), IIB (n 5 15), IIIB (n 5 36), and IV (n 5 4). Histologically, 56
tumors were classified as squamous cell carcinomas and 2 as adenocarcinomas.
The ages of the patients ranged from 28 to 85 years, with a median of 49 years.
DNA Isolation and Analysis of LOH. High molecular weight DNA from
tumor and peripheral blood samples were isolated using standard procedures of
proteinase K digestion, phenol-chloroform extraction, and ethanol precipita-
tion. A panel of 25 dinucelotide polymorphic markers were chosen on the basis
of their map position and heterozygosity (Table 1; Gene Map 994) and were
obtained from Research Genetics (Huntsville, AL). A standard PCR reaction
was carried out in a 10-ml reaction volume containing 1.5–2.5 mM MgCl2,
10–15% glycerol, 4 pmol of each primer (one-fifth of one of which was
end-labeled with [g-32P]dATP), 0.2 mM deoxynucleotide triphosphates, 25 ng
of DNA, and 0.3 unit of AmpliTaq DNA polymerase (Perkin-Elmer Corp.,
Branchburg, NJ). The amplification was carried out for 30 cycles at annealing
temperatures ranging from 50 to 58°C. The PCR products were denatured in
sequence stop buffer containing formamide and electrophoresed on a 6%
urea-containing polyacrylamide gel, and the dried gels were autoradiographed
for 4–16 h. Criteria applied for scoring LOH was described earlier (19). All
autoradiograms were independently scored visually by three investigators
(H. A. P., F. M., and V. V. V. S. M.). The definition of minimal region of
deletion was based on LOH of the loci that span common deletion in several
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tumors and retention of heterozygosity of adjoining markers at both the
boundaries in at least two tumors.
Mutation Analysis. SSCP analysis was performed on all 15 exons of the
PPP2R1B gene using primers flanking intronic sequences (18). PCR was
performed as described above except that 0.5 mCi of a [32P]dCTP was
included in the reaction instead of labeled primers. The PCR products were
diluted in 0.1% SDS/10 mM EDTA, denatured in sequencing stop buffer, and
run overnight in 6% nondenaturing polyacrylamide gels containing 10% glyc-
erol at room temperature. Dried gels were autoradiographed and examined for
conformational changes. Automated sequencing was performed on exons that
showed suggestive mutations using purified PCR products.
RESULTS
In the present study, a panel of 58 paired normal–tumor DNAs from
CCs were assayed for LOH using 25 polymorphic sequenced-tagged
sites (STSs) mapped to chromosome 11 (5 on 11p and 20 on 11q;
Table 1). The analysis revealed deletions in at least one locus in 46
(79%) tumors. Of these, 4 tumors (T-46, T-48, T-52, and T-114)
showed loss of one allele at all informative loci, suggesting genetic
monosomy of chromosome 11. The remaining 42 tumors showed
LOH at one or more loci while retaining heterozygosity at the remain-
ing loci, suggesting regional losses. These tumors with regional losses
were used to identify a pattern of minimal deletions. The frequency of
LOH varied among the markers from 14.6% (D11S911 at 11q13) to
60.6% (D11S4094 at 11q23.2; Table 1). The pattern of LOH identified
multiple regions of discrete deletions both on the 11p and 11q. The
frequency of LOH did not show any correlation with age, tumor stage,
size, or histology.
Deletions on 11p. Twenty-three (39.7%) tumors showed deletions
on the 11p, and 8 (4 with complete monosomy of chromosome 11) of
these showed LOH at all informative loci, suggesting monosomy of
11p. The remaining 15 tumors exhibited partial deletions. The patterns
of LOH identified two regions of minimal deletion, one at 11p15.11
and the other at 11p12–13. The 11p15 deletion spanned by the locus
D11S4189 showed LOH in 33.3% of informative cases where tumors
T-29 and T-79 exhibited deletions while retaining heterozygosity at a
proximal marker D11S4099. The second site of deletion at 11p12–13
spanned by the markers D11S4200 and D11S4083 exhibited LOH in
26 and 22%, respectively. This deletion was defined by tumors T-117
and T-75, with distal marker D11S4096 retaining heterozygosity,
whereas 3 other tumors (T-92, T-28 and T-29) exhibited LOH at
D11S4083 and retained heterozygosity at D11S4200. Thus, the pat-
terns of LOH on 11p identified two discrete regions of deletions
(Fig. 1).
Identification of 11q23 Minimal Deletion. The 11q LOH was
observed in 40 of 58 (69%) tumors studied. In addition to 4 tumors
with complete loss of chromosome 11, two others (T-105 and T-116)
showed LOH at all informative loci on 11q, suggesting monosomy.
The pattern of LOH in the remaining 34 tumors with interstitial allelic
deletions on 11q identified one common region of loss at 11q23.1–
q23.2 (Fig. 2). Of the 34 tumors with partial 11q LOH, 24 tumors
exhibited deletions at 11q23.1–23.2, and the remaining 10 showed
scattered deletions outside the 11q23 region (Fig. 2). The common
deleted region at 11q23.1–q23.2 spanned the loci D11S4167 (45.7%
LOH), D11S1353 (58.5% LOH), D11S4094 (60.6% LOH), and
D11S4144 (46.8% LOH). Boundaries of this deletion flanked by the
marker D11S925 proximally with retention of heterozygosity in 4
tumors (T-16, T-28, T-40, and T-112) and D11S933 distally with
retention of heterozygosity in two tumors (T-110 and T-76; Fig. 3).
Mutation Analysis of the PPP2R1B Gene. Mutations in the
PPP2R1B gene at 11q23 were earlier reported in lung and colon
carcinomas as a target of deletions in this region (18). To determine
whether the PPP2R1B gene is the target of 11q23 deletions in CCs,
we performed mutation analysis of the entire coding region on a panel
of 30 tumor DNAs that exhibited LOH on 11q23. All suspected SSCP
variants were sequenced in both orientations to identify the nature of
the mutations. This analysis identified three different types of se-
quence alterations in three tumors: the G 3 C transversion that
changes Ala6013 Pro (T-98); G3 A transition that changes Arg411
3 Gly (T-28, T-92); and G3 A transition that changes Gly903 Asp
(T-98). The Arg411 3 Gly and Gly90 3 Asp alterations in both
Fig. 1. Patterns of LOH on 11p in cervical
carcinoma. Fifteen tumors exhibiting partial dele-
tions are represented. Left, G-banded ideogram;
right of ideogram, corresponding loci. Patterns of
LOH are shown in squared boxes below tumor
numbers. f, LOH; o, retention of heterozygosity;
M, homozygous and uninformative; ND, not done.
Black vertical bars on the right, regions of minimal
deletion.







11p15.11 D11S4189 20.50 52/39 13 (33.3)
11p14 D11S4099 24.90 55/34 10 (29.4)
D11S4096 24.90 56/33 9 (27.3)
11p12–13 D11S4200 46.90 58/50 13 (26.0)
D11S4083 50.70 57/50 11 (22.0)
11q12–13.1 D11S4207 80.00 57/42 11 (26.2)
11q13.2–13.3 D11S911 84.20 58/48 7 (14.6)
D11S937 84.60 56/48 14 (29.2)
11q13.4–13.5 D11S4147 92.50 58/43 15 (34.9)
11q14.2–14.3 D11S4120 100.90 58/45 12 (26.7)
D11S898 103.10 58/45 17 (37.8)
D11S1339 104.80 58/37 10 (27.0)
11q21–22.1 D11S1343 106.50 56/22 9 (40.9)
D11S1347 110.30 55/36 11 (30.6)
11q22.2–22.3 D11S939 117.9 56/35 12 (34.3)
D11S1356 118.60 56/53 23 (43.4)
11q23.1 D11S925 123.50 58/44 19 (43.2)
D11S4167 124.60 58/46 21 (45.7)
11q23.2 D11S1353 127.80 56/41 24 (58.5)
D11S4094 129.00 55/33 20 (60.6)
D11S4144 129.50 58/47 22 (46.8)
D11S933 129.50 58/31 14 (45.2)
11q23.3 D11S934 131.70 56/35 11 (31.4)
11q24–25 D11S4131 143.80 58/40 18 (45.0)
D11S4085 147.20 58/37 14 (37.8)
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tumors were found to be homozygous, whereas the Ala6013 Pro was
heterozygous. The changes Ala601 3 Pro and Arg411 3 Gly were
found to be population variants because the similar alterations were
also seen in the corresponding control and unrelated normal individ-
uals (data not shown). The Gly903 Asp change was also found to be
present in the corresponding normal DNA from the patient T-98. The
sequence analysis suggests that the wild-type (normal) allele have
been deleted in the T-98 tumor DNA, consistent with the observation
of LOH at 11q23 (Fig. 2). The residual GGC90 signals seen in T-98
DNA may represent contaminating normal cells in the tumor tissue
compared with normal DNA from blood from the same patient (Fig.
4). Thus, the normal allele of the PPP2R1B is deleted by LOH in
T-98, and the variant allele is retained in this tumor.
DISCUSSION
Functional studies have identified that chromosome 11 carries a
gene(s) responsible for tumor suppression in CC (11–14). Allelotype
studies have further identified high frequency of LOH on 11q, con-
sistent with the presence of one or more TSGs on this chromosomal
arm (7–10, 15–16, 20). These studies, however, suffer from lack of
extensive and systematic deletion mapping analysis in delineating the
exact location of the TSG. In CC, only a few previous studies have
performed detailed deletion mapping in an attempt to identify the
critical regions of deletion. These studies identified at least two
putative TSG sites at 11q13 and 11q22–24 (15, 17, 21). Hampton et
al. (17) using 16 polymorphic markers on chromosome 11 in 32
patients have identified a minimal deleted region to a 35-cM genetic
distance at 11q23. More recently, Mugica-Van Herckenrode et al. (21)
have further restricted the region of deletion to a 19-cM genetic
distance at the 11q23 region using only four markers at this region.
These studies, thus, identified candidate TSG sites at 11q23 that may
be critical for the tumor formation in cervix uteri.
To further define the critical regions of deletion on chromosome 11,
we performed a systematic and high-density LOH mapping. The
pattern of allelic losses in the present study identified three discrete
regions of minimal deletions, two on 11p and one on 11q. The 11p
deletions were localized at p15.11 (13 of 39 informative cases; 33.3%
LOH) and p12–13 (17 of 52 informative cases; 32.7% LOH). The 11q
deletion was localized at 11q23.1–23.2 (30 of 57 informative cases;
Fig. 2. Patterns of LOH on 11q in cervical carcinoma. Thirty-four tumors exhibiting partial deletions are represented. Left, G-banded ideogram; right of ideogram, corresponding
polymorphic loci. Patterns of deletions shown in squared boxes below the tumor numbers. f, LOH; o, retention of heterozygosity; M, homozygous and uninformative; ND, not done.
Black vertical bar on the right, region of minimal deletion.
Fig. 3. Illustration of a common region of deletion at 11q23 by LOH analysis. Two
cases, T-21 (A) and T-110 (B), are represented. Tumor T-21 showing LOH at D11S4167
and D11S1353, while retaining the heterozygosity at a proximal D11S1356 and distal
D11S4144 markers. Tumor T-110 shows LOH at all markers except the distal D11S934.
N, normal; T, tumor; p, LOH; cen, centromere; tel, telomere. Tumor numbers are shown
on top of each panel, and markers are shown on the sides.
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52.6% LOH). The 11q23 region has been implicated previously in
CC, whereas the 11p deletions have not been reported earlier. Al-
though the frequencies of allelic deletions at 11p15 and 11p12–13
regions were low, the 11q23.1–23.2 region exhibited high frequency
of LOH.
The short arm of chromosome 11 between 11p11 and 11p15 has
been shown to contain genes controlling the regulation of HPV-16
viral early promoter (22). Whether the LOH seen at 11p in the present
study plays any role in HPV-induced transformation remains to be
seen. The 11p15 and 11p13 regions also exhibit genetic alterations in
a variety of tumor systems (23). At present, the significance of the low
frequency of LOH in these regions is not clear, and additional studies
are required to understand the importance of these genetic alterations.
In the present study, the 11q23 region exhibited the highest fre-
quency of LOH (60.6% LOH at D11S4094), suggesting that this
region contains a TSG critical for CC development. A number of
previous studies have also identified frequent LOH at 11q22–24
regions in CC (9–10, 17, 20–21).
The 11q22-q24 region has also been implicated in a variety of other
solid tumor types including carcinomas of breast (24–29), lung (30,
31), colon (32), ovary (33, 34), and oral (35, 36) carcinomas, malig-
nant melanoma (37, 38), and neuroblastoma (39). The chromosome
11q deletion maps generated by these studies have been reviewed, and
the results are summarized in Fig. 5. That 11q22–23 is the most
frequent target of LOH in solid tumors suggests that this region
contains one or more TSGs. Furthermore, review of the previous
studies revealed at least three distinct regions of deletions at 11q22–
23, a proximal region targeting between 106.5 and 116 cM, a second
region between 121 and 127 cM, and the distal region between 137
and 145 cM. The proximal deletion is frequently involved in breast,
lung, and malignant melanomas, and the middle region is a target in
cervical and breast carcinomas (Fig. 5). The third and the distal
regions between 137 and 145 cM may be a target in colon, ovarian,
and oral carcinomas. These data, thus, suggest that there are at least
three TSGs that may be the target of 11q23 deletions in various solid
tumor types.
The PPP2R1B gene, which maps to the proximal 11q22–23 region
between 106.5 and 116 cM, encodes the b-isoform subunit of serine/
threonine protein phosphatase 2A and was found to be mutated in
15% of lung and colon carcinomas (18). This region has also been
implicated previously in CC (17, 21). To find out whether PPP2R1B
is a candidate TSG for CC, we performed mutation analysis of the
entire gene and found four cases with a single nucleotide alteration.
Three of the four sequence alterations were confirmed as polymor-
phisms because they were also seen in matched normal DNAs and in
unrelated controls. The fourth case with codon GGA90 3 GAC
alteration was also present in matched-normal DNA but not in 100
additional normal DNAs (data not shown), suggesting that this may
represent a germ-line mutation. LOH analysis on this patient tumor
DNA showed loss of a normal wild-type allele, suggesting that this
may represent a pathogenic alteration. To see whether this change is
inherited, we studied four members of the family (son, daughter,
sister, and nephew) and found that the son and daughter inherited the
same variant but not by the sister and nephew. The PPP2R1B Gly90
3 Asp alteration was reported earlier in three tumors of non-small
cell lung carcinomas as pathogenic alteration (18). In another recent
study of ovarian carcinomas by Campbell and Manolitsas (40), this
change was reported as a nonpathological polymorphism. Our data,
however, support the view that the PPP2R1B Gly903 Asp alteration
may represent a germ-line change, and individuals carrying this
change may be susceptible to developing cervical or other types of
solid tumors. This, however, remains to be tested in families with
inherited cancer. The present data, however, conclusively exclude
PPP2R1B as a target of 11q23 somatic deletions in CC.
In the present study, we defined the minimal region of deletion at
11q23 in CC to span a 6-cM genetic distance between 123.4 and 129.5
cM interval (Fig. 5). This region is currently known to contain five
genes. These include U90916 mRNA of unknown function, zinc
finger protein 202 (ZNF202), LOH 11 chromosomal region 2
(LOH11CR2A), similar to heat shock cognate Mr 70,000 protein 10
(HSC71), and a protein kinase C substrate RC3 (neurogranin). Of
these, the genes LOH11CR2A and ZNF202 have been examined as
11q23 deletion targets in breast and lung carcinomas. Both the
LOH11CR2A and ZNF202 genes were identified in an effort to find a
TSG in the region between loci D11S1345 and D11S1328 deleted in
breast carcinoma (24, 41). However, no genetic alterations in the
support of the tumorigenic potential of these genes could be estab-
lished in breast carcinoma (24, 41). In addition to these known genes,
at least 28 UniGene clusters were mapped to this interval of minimal
deletion (Gene Map’995).
In the present study, we have defined a minimal region of deletion
5 Internet address: http://www.ncbi.nlm.nih.gov/genemap/map.cgi?CHR51.
Fig. 4. Mutation analysis of the PPP2R1B gene in cervical carcinoma. A, PCR SSCP
analysis of exon 3. Tumor numbers are indicated on top. p, conformational change. B and
C, PCR sequence analysis of T-98. Heterozygosity of A/G at amino acid 90 in normal
DNA (B) and Gly90 3 Asp alteration in tumor (C) are shown.
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at 11q23 in CC that may contain the critical TSG and excluded a
previously known tumor suppressor PPP2R1B as a target of 11q23
deletions in CC. The current definition of minimal deletion with the
available genomic resources in this region should aid in the identifi-
cation of the candidate TSG.
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